P16 Expression Is Lost in Severely Atypical Cellular Blue Nevi and Melanoma Compared to Conventional, Mildly, and Moderately Atypical Cellular Blue Nevi

Overview

Journal ISRN Dermatol

Specialty Dermatology

Date 2014 Mar 4

PMID 24587914

Citations 4

Authors

Laura M Chang

David S Cassarino

Affiliations

Soon will be listed here.

Abstract

Background. Significant decreases in p16 expression have been shown to occur in melanoma compared to Spitz tumors, and loss of p16 staining has been found to correlate with melanoma tumor progression. However, comparison of p16 between atypical cellular blue nevi (CBN) and melanoma has not been reported previously. Methods. p16 immunohistochemical staining was evaluated in 14 atypical CBN, 8 conventional and atypical melanocytic nevi, and 16 melanomas, including 4 malignant CBN. p16 staining intensity was graded on a scale of 0-3 and the percentage of melanocytes stained with p16 was determined. Results. p16 staining was significantly higher in all CBN as a group when compared to melanomas (P = 0.001) and malignant CBN (P = 0.00008). Higher p16 expression was also seen in mildly (P = 0.0002) and moderately atypical (P = 0.02), but not severely atypical, CBN compared to melanomas. Conclusions. p16 immunohistochemical expression is higher in mildly and moderately atypical CBN compared to severely atypical CBN and melanomas. In conjunction with additional markers and histology, p16 staining may be useful in confirming the benign nature of these tumors, but is not useful in distinguishing severely atypical CBN from malignant cases, consistent with the overlapping histologic features between these tumors.

Citing Articles

Cellular Blue Nevus Diagnosed following Excision of Melanoma: A Challenge in Diagnosis.

Jonjic N, Dekanic A, Glavan N, Prpic-Massari L, Grahovac B Case Rep Pathol. 2016; 2016:8107671.

PMID: 27313934 PMC: 4899595. DOI: 10.1155/2016/8107671.

Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Botti G, Marra L, Anniciello A, Scognamiglio G, Gigantino V, Cantile M Int J Clin Exp Pathol. 2015; 8(9):9742-51.

PMID: 26617684 PMC: 4637769.

A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma.

Uguen A, Talagas M, Costa S, Duigou S, Bouvier S, De Braekeleer M Diagn Pathol. 2015; 10:195.

PMID: 26503349 PMC: 4623282. DOI: 10.1186/s13000-015-0431-9.

Epigenetic effects of cadmium in cancer: focus on melanoma.

Venza M, Visalli M, Biondo C, Oteri R, Agliano F, Morabito S Curr Genomics. 2015; 15(6):420-35.

PMID: 25646071 PMC: 4311387. DOI: 10.2174/138920291506150106145932.

References

Soares de Sa B, Fugimori M, Ribeiro K, Duprat Neto J, Neves R, Landman G . Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas. Melanoma Res. 2009; 19(3):135-41. DOI: 10.1097/CMR.0b013e32831993f3. View

Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T . Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer. 1997; 74(3):255-9. DOI: 10.1002/(sici)1097-0215(19970620)74:3<255::aid-ijc4>3.0.co;2-y. View

Al Dhaybi R, Agoumi M, Gagne I, McCuaig C, Powell J, Kokta V . p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi. J Am Acad Dermatol. 2011; 65(2):357-363. DOI: 10.1016/j.jaad.2010.07.031. View

Ruiter D, van Dijk M, Ferrier C . Current diagnostic problems in melanoma pathology. Semin Cutan Med Surg. 2003; 22(1):33-41. DOI: 10.1053/sder.2003.50003. View

Stefanaki C, Stefanaki K, Antoniou C, Argyrakos T, Stratigos A, Patereli A . G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas. J Cutan Pathol. 2008; 35(9):799-808. DOI: 10.1111/j.1600-0560.2007.00912.x. View

de Andrade B, Leon J, Carlos R, Delgado-Azanero W, Mosqueda-Taylor A, de Almeida O . Immunohistochemical expression of p16, p21, p27 and cyclin D1 in oral nevi and melanoma. Head Neck Pathol. 2012; 6(3):297-304. PMC: 3422579. DOI: 10.1007/s12105-012-0334-y. View

Pavey S, Cummings M, Whiteman D, Castellano M, Walsh M, Gabrielli B . Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res. 2002; 12(6):539-47. DOI: 10.1097/00008390-200212000-00003. View

Murali R, McCarthy S, Scolyer R . Blue nevi and related lesions: a review highlighting atypical and newly described variants, distinguishing features and diagnostic pitfalls. Adv Anat Pathol. 2009; 16(6):365-82. DOI: 10.1097/PAP.0b013e3181bb6b53. View

Hilliard N, Krahl D, Sellheyer K . p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma. J Cutan Pathol. 2009; 36(7):753-9. DOI: 10.1111/j.1600-0560.2008.01154.x. View

10.

Reed J, Loganzo Jr F, Shea C, Walker G, Flores J, Glendening J . Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 1995; 55(13):2713-8. View

11.

Barnhill R, Argenyi Z, Berwick M, Duray P, Erickson L, Guitart J . Atypical cellular blue nevi (cellular blue nevi with atypical features): lack of consensus for diagnosis and distinction from cellular blue nevi and malignant melanoma ("malignant blue nevus"). Am J Surg Pathol. 2007; 32(1):36-44. DOI: 10.1097/PAS.0b013e3181573aaf. View

12.

Alonso S, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna M . Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol. 2003; 164(1):193-203. PMC: 1602212. DOI: 10.1016/s0002-9440(10)63110-0. View

13.

Karim R, Li W, Sanki A, Colman M, Yang Y, Thompson J . Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors. Int J Surg Pathol. 2009; 17(5):361-7. DOI: 10.1177/1066896909336177. View

14.

Zoroquiain P, Fernandes B, Gonzalez S, Novais G, Schalper K, Burnier Jr M . p16ink4a expression in benign and malignant melanocytic conjunctival lesions. Int J Surg Pathol. 2012; 20(3):240-5. DOI: 10.1177/1066896911435697. View

15.

Mihic-Probst D, Mnich C, Oberholzer P, Seifert B, Sasse B, Moch H . p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer. 2005; 118(9):2262-8. DOI: 10.1002/ijc.21608. View

16.

Ohsie S, Sarantopoulos G, Cochran A, Binder S . Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008; 35(5):433-44. DOI: 10.1111/j.1600-0560.2007.00891.x. View

17.

Wang Y, Uhara H, Yamazaki Y, Nikaido T, Saida T . Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma. Br J Dermatol. 1996; 134(2):269-75. View

18.

George E, Polissar N, Wick M . Immunohistochemical evaluation of p16INK4A, E-cadherin, and cyclin D1 expression in melanoma and Spitz tumors. Am J Clin Pathol. 2010; 133(3):370-9. DOI: 10.1309/AJCP52YVYCTLUOPI. View

19.

Tom W, Hsu J, Eichenfield L, Friedlander S . Pediatric "STUMP" lesions: evaluation and management of difficult atypical Spitzoid lesions in children. J Am Acad Dermatol. 2011; 64(3):559-72. DOI: 10.1016/j.jaad.2009.12.063. View

20.

Straume O, Sviland L, Akslen L . Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res. 2000; 6(5):1845-53. View